Keros Therapeutics (KROS) Other Gross PP&E Adjustments (2019 - 2025)
Historic Other Gross PP&E Adjustments for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to -$17.5 million.
- Keros Therapeutics' Other Gross PP&E Adjustments rose 1190.54% to -$17.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.5 million, marking a year-over-year increase of 1190.54%. This contributed to the annual value of -$19.6 million for FY2024, which is 321.1% up from last year.
- According to the latest figures from Q3 2025, Keros Therapeutics' Other Gross PP&E Adjustments is -$17.5 million, which was up 1190.54% from -$18.1 million recorded in Q2 2025.
- Over the past 5 years, Keros Therapeutics' Other Gross PP&E Adjustments peaked at $1.1 million during Q4 2021, and registered a low of -$20.3 million during Q4 2023.
- For the 5-year period, Keros Therapeutics' Other Gross PP&E Adjustments averaged around -$10.1 million, with its median value being -$14.6 million (2024).
- As far as peak fluctuations go, Keros Therapeutics' Other Gross PP&E Adjustments soared by 9647.27% in 2021, and later plummeted by 340536.91% in 2023.
- Quarter analysis of 5 years shows Keros Therapeutics' Other Gross PP&E Adjustments stood at $1.1 million in 2021, then tumbled by 1196.59% to -$12.2 million in 2022, then plummeted by 65.96% to -$20.3 million in 2023, then grew by 3.21% to -$19.6 million in 2024, then increased by 11.01% to -$17.5 million in 2025.
- Its last three reported values are -$17.5 million in Q3 2025, -$18.1 million for Q2 2025, and -$18.7 million during Q1 2025.